CN104513298B - 一种表达鸡传染性法氏囊可溶性vp 2-4-3多肽的方法 - Google Patents
一种表达鸡传染性法氏囊可溶性vp 2-4-3多肽的方法 Download PDFInfo
- Publication number
- CN104513298B CN104513298B CN201410753079.5A CN201410753079A CN104513298B CN 104513298 B CN104513298 B CN 104513298B CN 201410753079 A CN201410753079 A CN 201410753079A CN 104513298 B CN104513298 B CN 104513298B
- Authority
- CN
- China
- Prior art keywords
- polypeptides
- expression
- solubility
- antigen
- cloacal bursa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 31
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 24
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 24
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 21
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 19
- 241001260012 Bursa Species 0.000 title claims abstract description 17
- 230000014509 gene expression Effects 0.000 title abstract description 12
- 238000000034 method Methods 0.000 title abstract description 7
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000013612 plasmid Substances 0.000 claims description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108010079246 OMPA outer membrane proteins Proteins 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 101150028074 2 gene Proteins 0.000 claims 2
- 230000006798 recombination Effects 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 2
- 210000001669 bursa of fabricius Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 230000003248 secreting effect Effects 0.000 abstract description 13
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 210000003000 inclusion body Anatomy 0.000 abstract description 5
- 238000000746 purification Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 abstract description 3
- 230000009465 prokaryotic expression Effects 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 231100000284 endotoxic Toxicity 0.000 abstract description 2
- 230000002346 endotoxic effect Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 230000002101 lytic effect Effects 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 8
- 241000702626 Infectious bursal disease virus Species 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000027312 Bursal disease Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101500026380 Mus musculus Endostatin Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical group CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410753079.5A CN104513298B (zh) | 2014-12-09 | 2014-12-09 | 一种表达鸡传染性法氏囊可溶性vp 2-4-3多肽的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410753079.5A CN104513298B (zh) | 2014-12-09 | 2014-12-09 | 一种表达鸡传染性法氏囊可溶性vp 2-4-3多肽的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104513298A CN104513298A (zh) | 2015-04-15 |
CN104513298B true CN104513298B (zh) | 2018-07-17 |
Family
ID=52789192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410753079.5A Active CN104513298B (zh) | 2014-12-09 | 2014-12-09 | 一种表达鸡传染性法氏囊可溶性vp 2-4-3多肽的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104513298B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111569056B (zh) * | 2020-05-26 | 2022-09-27 | 山东信得科技股份有限公司 | 一种猪轮状病毒疫苗、制备该疫苗的抗原及其编码序列 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1754959A (zh) * | 2004-09-27 | 2006-04-05 | 长江大学 | 一种传染性法氏囊病基因工程亚单位疫苗的制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7678883B2 (en) * | 2007-07-25 | 2010-03-16 | E.I. Du Pont De Nemours And Company | Solubility tags for the expression and purification of bioactive peptides |
-
2014
- 2014-12-09 CN CN201410753079.5A patent/CN104513298B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1754959A (zh) * | 2004-09-27 | 2006-04-05 | 长江大学 | 一种传染性法氏囊病基因工程亚单位疫苗的制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
Infectious bursal disease virus mRNA for VP2-4-3 polyprotein, partial cds;Tsukamoto,K. et al.;《Genbank》;19991204;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN104513298A (zh) | 2015-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108680744B (zh) | 一种检测新型鸭呼肠孤病毒抗体的间接elisa检测试剂盒及应用 | |
CN104805106B (zh) | 含tgev及pedv保护性抗原的融合基因及其编码蛋白和应用 | |
CN111234036A (zh) | 非洲猪瘟病毒p72融合蛋白及其制备方法和应用 | |
Maeda et al. | Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model | |
CN104292300B (zh) | 口蹄疫病毒o型毒株(o/by/cha/2010)中vp1、vp2和vp4三个结构蛋白的表位最小基序肽及其应用 | |
CN113637056A (zh) | 一种用于鉴别牛种布鲁氏菌与其它种布鲁氏菌的试剂盒 | |
CN115427071A (zh) | 包含ltb和病原性抗原的组合物及其用途 | |
CN102210860B (zh) | 一种结核分枝杆菌tb10.4-f1融合蛋白疫苗及制备方法 | |
CN109293750B (zh) | 一种铜绿假单胞菌疫苗重组蛋白sbp及其制备方法及应用 | |
CN104513298B (zh) | 一种表达鸡传染性法氏囊可溶性vp 2-4-3多肽的方法 | |
CN103304663B (zh) | 一种鸡源性抗鸡新城疫病毒p蛋白的单链抗体、其制备方法及其用途 | |
CN101607081B (zh) | 布鲁氏菌疫苗及疫苗用抗原蛋白的制备方法 | |
CN106397546B (zh) | 一种o型口蹄疫病毒人工重组抗原及其制备与应用 | |
CN115926000A (zh) | 一种猪丹毒rSpaA-Fc融合蛋白及其在疫苗中的应用 | |
Yan et al. | Preparation of a new monoclonal antibody against subgroup A of avian leukosis virus and identifying its antigenic epitope | |
CN110028559B (zh) | 一种铜绿假单胞菌疫苗重组蛋白及其编码基因和它们的应用 | |
CN113754782A (zh) | 一种幽门螺旋杆菌卵黄抗体及其制备方法和应用 | |
CN108359685B (zh) | 一种具有免疫保护作用的迟缓爱德华菌外膜蛋白TolC | |
CN105524148A (zh) | 一种用作猪肺炎支原体疫苗的重组蛋白及其制备方法和应用 | |
CN109207504B (zh) | 一种有效免疫ib与nd的唾液乳酸杆菌的制备方法 | |
CN102731649B (zh) | 一种鸡源性抗鸡新城疫病毒的单链抗体、及其制备方法和用途 | |
CN110376385B (zh) | 一种基因工程表达qx型鸡传染性支气管炎病毒s1蛋白抗原的制备方法与应用 | |
Dantas et al. | A protein expression system for tandem affinity purification in Xanthomonas citri subsp. citri | |
CN113717292A (zh) | 一种针对鸡坏死性肠炎的融合蛋白疫苗及其制备方法 | |
CN102657865A (zh) | 利用转基因球虫向哺乳动物肠道靶向运送蛋白或抗原的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for expressing soluble VP 2-4-3 polypeptide of chicken infectious bursa Effective date of registration: 20211222 Granted publication date: 20180717 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2021980015708 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221223 Granted publication date: 20180717 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2021980015708 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Method for Expressing Soluble VP 2-4-3 Polypeptide from Infectious Bursa of Chicken Effective date of registration: 20230608 Granted publication date: 20180717 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2023980043376 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20180717 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: SHANDONG SINDER TECHNOLOGY Co.,Ltd. Registration number: Y2023980043376 |